Abbott's Volt PFA System Used in Procedures for Patients with Abnormal Heart Rhytms
19 January 2024 - 1:48AM
Dow Jones News
By Denny Jacob
Abbott Laboratories disclosed that the first global procedures
have been conducted using its new Volt Pulsed Field Ablation system
to treat patients battling common abnormal heart rhythms such as
atrial fibrillation.
The healthcare-products manufacturer said over 30 patients were
treated in Australia as part of its clinical study evaluating the
safety and effectiveness of its Volt PFA system. The company
expects approval for its U.S. clinical trial for the system in the
first half of this year.
Abbott said patients requiring a cardiac ablation procedure to
treat conditions like atrial fibrillation received radiofrequency
ablation, which uses heat to destroy tissue responsible for erratic
heart signals, or cryogenic ablation, which freezes tissue. The
company's system uses high-energy electrical impulses to destroy
the cells causing abnormal heart rhythms, rather than heat or
extreme cold, which it said can reduce the risk of damaging
adjacent tissue in patients with complex disease or anatomy.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 18, 2024 09:33 ET (14:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Dec 2023 to Dec 2024
